---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-085558"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:07:13.292062+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics reports Q3 net loss $2.3M; INT230-6 shows 93% disease control in sarcoma

## Summary
- Phase 1/2 INT230-6 data in refractory soft tissue sarcoma: 93% disease control rate, survival extension ~15 months vs synthetic control.
- Received Orphan Drug Designation for all three components of INT230-6 for soft tissue sarcoma.
- Completed upsized IPO with full over-allotment, net proceeds $20.2M; cash $15.6M as of Sept 30, 2023.
- R&D expenses $1.4M, G&A $1.1M; net operating loss $2.3M for Q3 2023.
- On track to file IND for Phase 3 study in sarcoma and report Phase 2 breast cancer results by end of 2023.

## SEC filing metadata
- accession: 0001213900-23-085558
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000121390023085558/0001213900-23-085558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000121390023085558/ea188196-8k_intensity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-085558
- JSON: https://secwatch.observer/filing/0001213900-23-085558.json
- Plain text: https://secwatch.observer/filing/0001213900-23-085558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.